ARTICLE
13 April 2026

Prosecution History Estoppel: Navigating Limits On Equivalents In Patent Litigation

FH
Finnegan, Henderson, Farabow, Garrett & Dunner, LLP

Contributor

Finnegan, Henderson, Farabow, Garrett & Dunner, LLP is a law firm dedicated to advancing ideas, discoveries, and innovations that drive businesses around the world. From offices in the United States, Europe, and Asia, Finnegan works with leading innovators to protect, advocate, and leverage their most important intellectual property (IP) assets.
In patent litigation, patentees may invoke the doctrine of equivalents to capture devices or methods that fall outside the literal language of the asserted claims. Yet one doctrinal constraint, prosecution history estoppel, can preclude such arguments when claim scope...
United States Intellectual Property
Daniel Cooley’s articles from Finnegan, Henderson, Farabow, Garrett & Dunner, LLP are most popular:
  • with Senior Company Executives, HR and Finance and Tax Executives
  • in European Union
  • in European Union
  • in European Union
  • with readers working within the Aerospace & Defence and Technology industries

The Highlights

  1. Prosecution history estoppel can significantly limit reliance on the doctrine of equivalents: While patentees may seek to capture non‑literal infringement through equivalence arguments, amendments or statements made during prosecution can bar that approach by signaling a surrender of claim scope.

  2. Both claim amendments and prosecution arguments can create estoppel: Estoppel is not limited to narrowing amendments made for patentability; clear and unequivocal statements distinguishing prior art can also constrain claim scope in later litigation—sometimes unintentionally.

  3. Prosecution decisions have lasting litigation consequences: The article underscores the importance of strategic prosecution drafting and argumentation, as early choices can determine infringement outcomes, settlement leverage, and enforcement flexibility years later.

In patent litigation, patentees may invoke the doctrine of equivalents to capture devices or methods that fall outside the literal language of the asserted claims. Yet one doctrinal constraint, prosecution history estoppel, can preclude such arguments when claim scope has been narrowed or otherwise surrendered during prosecution. Understanding prosecution history estoppel is important for both patent owners and accused infringers, as it can shape litigation strategy throughout the course of a case.

I. Background

In certain limited situations, an accused product or process that does not literally infringe an asserted patent by practicing all claim limitations may nevertheless be found to infringe under the doctrine of equivalents if “there is ‘equivalence’ between the elements of the accused product or process and the claim elements of the patented invention.”1

Prosecution history estoppel limits the application of the doctrine of equivalents and reflects the principle that amendments and arguments made during the prosecution of a patent application can limit the scope of the resulting issued patent.2Under this doctrine, a patentee may be barred from asserting subject matter surrendered during prosecution either through claim amendments or arguments.3

Under prosecution history estoppel, a narrowing amendment made to achieve patentability gives rise to a presumption that the patentee “surrender[ed] all equivalents to the amended claim element.”4A patentee seeking to overcome this presumption must show that the alleged equivalent was unforeseeable at the time of the amendment and that the amendment bears no more than a tangential relation to the equivalent, or that some other reason justifies preserving the equivalent.5

II. Amendment-Based Estoppel

Amendment-based estoppel arises when a claim is narrowed to secure patentability, for example, to overcome prior art or satisfy other statutory requirements.6In such circumstances, courts generally view the amendment as a clear and unmistakable surrender of claim scope that might otherwise be recaptured through an equivalence argument.7Because the patentee chose to surrender certain subject matter to obtain allowance, equity and fairness dictate that the patentee cannot later reclaim that subject matter through litigation. A narrowing amendment may be strictly construed to foreclose a patentee’s ability to assert the doctrine of equivalents as to that element.

III. Argument-Based Estoppel

Prosecution history estoppel is not limited to formal claim amendments. Argument-based estoppel can arise from statements made during prosecution to distinguish prior art or explain claim scope.8When considering argument-based estoppel arguments, courts focus on whether the patentee’s remarks were sufficiently clear and unequivocal to signal a surrender of subject matter.9

In this context, even when the claims themselves are not amended, the patentee’s arguments to an examiner may limit how those claims are interpreted in later litigation. For instance, a patentee’s characterization of an invention to overcome a rejection may be read as narrowing the scope of what was claimed. If the patentee clearly distinguished certain subject matter during prosecution, those statements can foreclose a doctrine of equivalents theory covering the subject matter during litigation under prosecution history estoppel.

Because argument-based estoppel focuses on the content and context of statements made during prosecution, strategic responses during prosecution are essential to preserving equivalents. A seemingly benign explanation of claim distinctions may later be cited as a binding surrender, particularly when examined alongside other prosecution history.

IV. Strategic Considerations for Litigation and Prosecution

For accused infringers, meticulous review of prosecution history remains a core task in early case assessment. Identifying potentially estopping amendments and arguments can enable an accused infringer to advance non-infringement positions and foreclose equivalency arguments.

For patent owners, an analysis of how arguments and amendments may later be construed is equally important. Where possible, patent owners should frame responses to office actions in ways that minimize unnecessary narrowing and avoid unintended characterizations that could later result in estoppel. Coordinating prosecution with anticipated litigation risks can help preserve flexibility.

V. Conclusion

Prosecution history estoppel’s practical impact in litigation is significant as it can narrow claim scope, dictate infringement outcomes, and influence settlement leverage. Patent owners should approach both prosecution and litigation with an eye towards how statements and amendments made during prosecution may shape, or even decide, later disputes.

By recognizing estoppel’s reach and crafting thoughtful prosecution records, patent owners can better manage enforcement risk and accused infringers can more effectively exploit historical record evidence to support noninfringement positions.

Footnotes

1 Warner-Jenkinson Co., Inc. v. Hilton Davis Chemical Co., 520 U.S. 17, 21, 29 (1997).

2 Festo Corp. v. Shoketsu Kinzoku Kogyo Kabushiki Co., Ltd., 535 U.S. 722, 733–34 (2002).

3 Pall Corp. v. Hemasure Inc., 181 F.3d 1305, 1311 (Fed. Cir. 1999) (“Prosecution history estoppel bars a patentee from imposing liability for infringement by an otherwise equivalent device or method, when the claim scope that would have reached the accused device or method was relinquished by the patentee in order to avoid the prior art.”).

4 Festo Corp., 535 U.S. at 727.

5 Id. at 740-41.

6 Id. at 733-35.

7 Exhibit Supply Co. v. Ace Patents Corp., 315 U.S. 126, 136-37 (1942) (“By the amendment [the patentee] recognized and emphasized the difference between the two phrases and proclaimed his abandonment of all that is embraced in that difference. The difference which he thus disclaimed must be regarded as material, and since the amendment operates as a disclaimer of the difference it must be strictly construed against him.”).

8 Hester Industries, Inc. v. Stein, Inc., 142 F.3d 1472, 1480, 46 U.S.P.Q.2d 1641 (Fed. Cir. 1998).

9 Amgen Inc. v. Coherus BioSciences Inc., 931 F.3d 1154, 1161 (Fed. Cir. 2019)

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

[View Source]

Mondaq uses cookies on this website. By using our website you agree to our use of cookies as set out in our Privacy Policy.

Learn More